RNTX

+ Watchlist + Portfolio

Rein Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.79
52-Week Range: $0.69 – $2.18
Market Cap: $68.46M
P/E (TTM): —
EPS (TTM): -1.68
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -163.36%
Return on Assets: -32.10%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.40
Debt/Equity: 0.42
Total Debt: $4.92M
Free Cash Flow: $-8.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $114.43M

RNTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.97M	$3.99M	$14.25M	$11.03M
Selling, General & Admin	$9.68M	$11.36M	$13.86M	$10.90M
Operating Expenses	$27.65M	$15.35M	$28.11M	$21.93M
Operating Income	-$27.65M	-$15.35M	-$28.11M	-$21.93M
EBITDA	-$27.48M	-$15.23M	-$28.05M	-$21.93M
Pretax Income	-$27.33M	-$15.68M	-$64.43M	-$50.58M
Income Tax	—	$0.00	-$1.54M	-$712.00K
Net Income	-$27.33M	-$15.73M	-$62.88M	-$49.87M
Diluted EPS	-6.02	-3.42	-3.51	-1.96
Diluted Shares	4.54M	4.60M	17.94M	25.44M

RNTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.19M	$17.31M	$12.87M	$3.21M
Current Assets	$21.87M	$18.27M	$13.66M	$4.33M
Total Assets	$22.01M	$106.01M	$62.19M	$24.16M
Current Liabilities	$3.38M	$4.38M	$5.75M	$6.18M
Total Debt	$33.00K	$48.00K	$0.00	—
Total Liabilities	$3.38M	$99.12M	$52.80M	$52.24M
Retained Earnings	-$272.79M	-$288.52M	-$351.40M	-$401.27M
Shareholders' Equity	$18.62M	$6.89M	$9.39M	-$28.09M
Working Capital	$18.49M	$13.88M	$7.91M	-$1.85M

RNTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$24.86M	-$19.81M	-$22.29M	-$19.36M
Free Cash Flow	-$24.86M	-$19.81M	-$22.29M	-$19.36M
Depreciation & Amortisation	$169.00K	$119.00K	$63.00K	$1.00K
Stock-Based Compensation	$2.08M	$1.19M	$1.12M	$2.22M
Investing Cash Flow	$26.46M	$16.20M	$0.00	—
Financing Cash Flow	$0.00	$15.79M	$17.82M	$9.76M
Net Change in Cash	$1.59M	$12.18M	-$4.47M	-$9.61M

RNTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.05M	$4.29M	$1.68M	$2.00M	$3.07M
Selling, General & Admin	$2.56M	$2.58M	$3.81M	$1.96M	$2.16M
Operating Expenses	$5.61M	$6.87M	$5.49M	$3.96M	$5.23M
Operating Income	-$5.61M	-$6.87M	-$5.49M	-$3.96M	-$5.23M
EBITDA	-$5.61M	-$6.87M	-$5.49M	-$3.96M	-$5.23M
Pretax Income	-$5.50M	-$6.82M	-$5.58M	-$32.68M	-$5.84M
Net Income	-$5.50M	-$6.82M	-$5.58M	-$31.97M	-$5.84M
Diluted EPS	-0.25	-0.28	-0.21	—	-0.19
Diluted Shares	21.92M	24.19M	26.36M	—	30.35M

RNTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$7.43M	$5.72M	$4.05M	$3.21M	$4.45M
Current Assets	$8.33M	$6.60M	$5.17M	$4.33M	$5.45M
Total Assets	$57.63M	$57.48M	$53.71M	$24.16M	$26.29M
Current Liabilities	$5.98M	$7.69M	$5.74M	$6.18M	$13.64M
Total Debt	—	—	—	—	$4.92M
Total Liabilities	$52.75M	$54.47M	$52.52M	$52.24M	$59.70M
Retained Earnings	-$356.90M	-$363.72M	-$369.30M	-$401.27M	-$407.11M
Shareholders' Equity	$4.87M	$3.01M	$1.19M	-$28.09M	-$33.41M
Working Capital	$2.35M	-$1.09M	-$570.00K	-$1.85M	-$8.18M
Net Debt	—	—	—	—	$478.00K

RNTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.17M	-$6.42M	-$3.55M	-$3.22M	-$3.42M
Free Cash Flow	-$6.17M	-$6.42M	-$3.55M	-$3.22M	-$3.42M
Depreciation & Amortisation	$0.00	$1.00K	$0.00	$0.00	—
Stock-Based Compensation	$264.00K	$256.00K	$1.45M	$257.00K	$156.00K
Financing Cash Flow	$738.00K	$4.71M	$1.90M	$2.40M	$4.65M
Net Change in Cash	-$5.44M	-$1.71M	-$1.65M	-$815.00K	$1.23M

Market Snapshot

About

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for serious diseases. The company utilizes innovative drug discovery platforms and technologies to advance its pipeline of product candidates. Rein Therapeutics aims to address unmet medical needs through its research and development programs.